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Introduction 
Lung cancer is the most common lethal cancer in 
men and the sixth most common among women 
worldwide (1). Its devastating incidence and clinical 
seriousness have stimulated innumerable researches 
directed toward any possible approach. One of these 
approaches was the quest for biological markers 
capable of helping clinicians in the process of diag- 
nosis, staging, disease monitoring and prognostica- 
tion. Serum tumour markers (TMs) may be defined 
as substances produced by tumour cells, indicative of 
their presence, which are released into the blood- 
stream where they may be assessed (2). None of the 
TMs are completely tumour-specific, since almost all 
can be detected in the tissues or blood of patients 
with benign disease as well as in normal control 
subjects. Lung tumour markers fall into several cat- 
egories including peptide and non-peptide hormones, 
oncofetal proteins, enzymes, structural proteins and 
membrane antigens (2,3). Sensitivity and specificity 
are parameters that give information on the validity 
of a test. These parameters are calculated correlating 
the serum concentration of TMs with clinical and 
radiological findings. Marker values are classified as 
true (or false) positive if high in presence (or absence) 
of tumour, and true (or false) negative if they are 
within the normal range in control subjects (or in 
patients with cancer). Serum tumour markers may be 
helpful in screening and early diagnosis of cancer, in 
the initial assessment of the extent of the disease, and 
in monitoring the tumour growth (or tumour volume 
reduction) once cancer has been diagnosed and treat- 
ment started. They may also give insight into histo- 
genesis, inter-relationships and biological behaviour 
of tumours (2). Many TMs can also be evaluated as 
prognostic factors, either alone or in combination 
with other histopathological, biochemical and 
clinical variables (4). 
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This paper reviews the serum tumour markers 
which are most useful in the clinical management of 
lung cancer, as well as the new, most promising TMs 
(Table 1). 
Carcinoembryonic Antigen (CEA) 
Among the numerous biomarkers known up to 
now, carcinoembryonic antigen (CEA) has certainly 
been the most extensively used. Carcinoembryonic 
antigen is an oncofetal protein normally present 
during fetal life, which occurs at low concentrations 
in adults, and circulates in high concentrations in 
patients with certain malignancies, particularly epi- 
thelial tumours (5). Abnormally high CEA levels 
have been found in 40-80% of non-small cell lung 
cancer (NSCLC) patients, with lower sensitivity in 
early stage cancer than in advanced cancer (610). It 
is clearly marked in patients with adenocarcinoma 
(11,12). A good relationship between CEA levels 
and treatment response has been demonstrated both 
in small cell lung cancer (SCLC) and NSCLC 
(6,9,13,14). Recently Icard et al. (15) have demon- 
strated that patients who underwent resection of 
stage I or II NSCLC with pre-operative CEA levels 
under 30 ng ml - ’ had significantly longer survival 
than patients with CEA above 30 ng ml - ‘. Virtually 
all patients with high CEA levels (> 50 ng ml - ‘) died 
within 2 yr. Therefore, these patients must be highly 
Table I List of reviewed tumour markers in lung cancer 
Carcinoembryonic antigen (CEA) 
Tissue polypeptide antigen (TPA) 
Squamous cell carcinoma antigen (SCC-Ag) 
CYFRA 21-1 
Neural cell adhesion molecule (NCAM) 
Neuron-specific enolase (NSE) 
Creatine-phosphokinase-BB (CPK-BB) 
Chromogranin A (ChrA) 
Soluble interleukin-2 receptor (sIL-2R) 
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suspected of having metastases even if operative 
staging indicates a limited disease. Generally, CEA 
levels vary along with changes of disease status, or 
may precede their clinical recognition. Persistently 
elevated post-operative values have been shown to 
indicate residual disease and poor prognosis (9). In 
392 carefully evaluated patients with resected stage I 
NSCLC, Gail et al. (16) found CEA to be an 
independent indicator of increased risk of recurrence. 
Other studies confirmed the correlation between 
CEA, usually by univariate methods, and survival 
(6,8,9,13,17,18). Conflicting results were obtained 
in studies using multivariate methods (8,19,29). 
Recently, CEA was found to be strongly predictive of 
the outcome of 360 patients with squamous..,cell lung 
cancer, but of little or no value when multiple factors 
were jointly considered (18). Carcinoembryonic anti- 
gen only emerged as a significant independent prog- 
nostic factor after the artificial exclusion of stage and 
related variables (18). 
Tissue Polypeptide Antigen (TPA) 
The cytoskeleton is a complex filamentous cyto- 
plasmic structure that may influence the cell dynamic 
morphology in the tissue environment (21). It is 
composed of different types of filaments with differ- 
ent sites: actin; intermediate filaments; myosine and 
microtubules. Cytocheratins are the major compo- 
nent of intermediate filaments (22). Following the 
suggestions by Debus et al. (23), these can be sub- 
divided into 20 different cytocheratins, according to 
their molecular weight and isoelectric point in two- 
dimensional electrophoresis. The cytocheratin family 
is expressed by all epithelial cells and appears to be a 
useful marker of epithelial differentiation (23-26). 
Tissue polypeptide antigen (TPA) is a chemically well 
defined substance (27) identified in 1957 (28). Three 
monoclonal antibodies used in the diagnostic assay 
identify three antigens corresponding to cytocher- 
atins number 8, 18, and 19 (29). Tissue polypeptide 
antigen is produced and released by proliferating cells 
(30-32). Thus, the concentration of the antigens is an 
indicator of the rate of cell division and tumour 
aggressiveness, and, consequently, of the host sur- 
vival (2).Tissue polypeptide antigen can be detected 
in the serum and urine of patients with a wide variety 
of tumours (33-38) including bronchial carcinoma 
(3943). Serum determinations of TPA seem effective 
in all lung cancer histotypes, and are probably more 
useful than for any other marker (44,45). In patients 
with any histotype of bronchial carcinoma, the pre- 
treatment level of TPA has been shown, by our team 
and other authors, to correlate positively with either 
primary tumour characteristics, or the nodal involve- 
ment, or the metastatic spread (9,39,41,43,44,46,47). 
Several studies have also indicated that post- 
treatment TPA assays tend to vary in accordance 
with changes in disease status, as assessed by the 
categories of treatment response (9,44,46,47), and 
may sometimes precede them (43). Five studies with 
several hundred patients have clearly shown that this 
marker is well correlated with the prognosis of lung 
cancer, and this correlation persists when numerous 
other prognostic factors are taken into account 
(9,20,43,44,48). In a recent study (18), TPA was also 
proved to be an independent and strong prog- 
nostic indicator in squamous cell lung cancer. More 
recently, the yield of TPA in the pre-treatment 
assessment of NSCLC was determined in com- 
parison with a baseline clinical evaluation and 
a multi-organ computed tomography (CT) (49). 
Using appropriate threshold values of TPA, 
it was possible to predict NSCLC resectability with 
an accuracy similar to that routinely achieved by 
CT (Fig. 1). 
Squamous Cell Carcinoma-Related Antigen 
(SCC-Ag) 
Squamous cell carcinoma (SCC)-related antigen, 
also known as tumour-associated antigen or TA-4, is 
a protein with a molecular weight of approximately 
48 000 daltons originally isolated in 1977 by Kato 
and Torigoe from squamous cell carcinomas of the 
cervix (50). Successively, a commercial radioimmuno- 
assay was developed which has proved the utility of 
this marker in the control of treatment and in the 
detection of cervical SCC recurrence (51-53). After- 
wards, the value of this marker was investigated in 
SCC of other origins (larinx, esophagus, oral and 
facial tumours etc.). The first results seem to suggest 
a moderate clinical usefulness of the marker, particu- 
larly in the follow-up of patients, in spite of a low 
sensitivity (54,55). In lung carcinoma, the picture is 
not so clear: in fact, the reported true positivity rates 
of SCC varied enormously, probably due to the 
policlonal or monoclonal antibody employed in the 
radioimmunoassay or to the influence of renal failure 
on SCC-Ag levels (54,56,57). Fischbach and Rink 
(57) reported a detection rate of 53%, Castelli et al. 
(58) reported a detection rate of 55%, and Ebert et al. 
(59) reported a detection rate of 78%. On the con- 
trary, Body et al. (60) and Lorenz et al. (61) reported 
detection rates of 31-35%. SCC-Ag is not a specific 
marker for SCC, since elevated values were also 
found in other cell types of lung carcinoma, particu- 
larly in adenocarcinoma and large cell carcinomas 
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Fig. I Diagnostic accuracies of the clinical baseline evaluation and computer tomography of brain, thorax, and abdomen, 
and tissue polypeptide antigen (TPA) (cutoff points: up to 110 U I - ‘, between 11 l-160 U 1~ ‘, above 160 U l- ‘). Values 
refer to the capability of detecting either full operability (Stages I and II, 1987 UICC classification), possible operability 
(Stage III) or full inoperability (Stages IIIb and IV). Solid bars, accuracy; 0, C.I. 95% (max); 0, C.I. 95% (min). Source: 
Buccheri and Ferrigno (49). 
(62,63). Its levels seem unrelated to tumour size, the 
extent of lymph node involvement, or the presence of 
metastases in distant organs; neither are these levels 
related to tumour cell differentiation (63). On the 
other hand, the value of pre-treatment SCC-Ag was 
emphasized as a prognostic factor for patients with a 
SCC of the lung (11,60,63). 
CYFRA 21-1 
CYFRA 21-1 is a cytoskeleton marker. Cyto- 
keratin 19 (CK 19) has a low molecular weight of 40 
kDa. It is present and immunohistochemically detect- 
able in the cytoplasm of epithelial tumour cells, 
including bronchial cancer cells (24,26), and CK 19 
fragments may be released in the serum owing to cell 
lysis or tumour necrosis. They can be used as a 
tumour marker for lung cancer, and can be measured 
by a new immunoradiometric assay, the CYFRA 
21-1 (64). Several studies have been made in the last 
few years indicating a high potential of this marker in 
NSCLC (6466). It has been demonstrated that the 
CYFRA 21-1 serum assay is significantly more 
sensitive for SCC than for all other histological lung 
cancer subtypes (65,67,68). In the first European 
multicentre study on CYFRA 21-1, Rastel et al. (68) 
investigated the serum levels of CYFRA 21-1, CEA, 
SCC-Ag and TPA. The sensitivity of CYFRA 21-1 
for SCLC was 16% (n=74), compared to 41% for 
NSCLC (n = 547). In histological subgroups, sensitiv- 
ity was 57% for squamous, 34% for undifferentiated 
large cell carcinoma, and 27% for adenocarcinoma. 
In SCC, the sensitivity of TPA, SCC-Ag and CEA 
was 46%, 30% and 25% respectively. Therefore 
CYFRA 21-1 appeared to be the best tumour marker 
for squamous cell lung cancer. Serum levels of 
CYFRA 21-1 are related to the tumour mass: the 
sensitivity for stages IIIa and IIIb is 43% and 79%, 
respectively (68). High values in asymptomatic 
Tl/T2NO/Nl patients may indicate the presence of 
(micro) metastases, and may prompt the clinician to 
perform further clinical investigations (68). Very 
recently, Pujol et al. (66) have demonstrated in a 
prospective study of 165 patients that CYFRA 21-1 
has an independent prognostic value and that its 
serum level helps predict the resectability of NSCLC. 
Serial determinations of CYFRA 21-1 were useful 
after surgical treatment of patients with SCC (69). A 
post-operative recurrence was observed in 9 of 10 
patients showing increased CYFRA 21-1 concentra- 
tions, while 48 of 54 (89%) patients with normal 
CYFRA 21-1 showed a stable disease-free status. In 
multivariate analysis, increased serum levels were 
found to be significantly associated with higher risk 
of recurrence (69). These observations are consistent 
with preliminary data from other authors (70,71), 
who also found CYFRA 21-1 able to predict both 
success and failure of therapy, as well as relapses, 
prior to clinical signs. Recently Van der Gaast et ul. 
(72) confirmed the usefulness of this marker in 
monitoring the status of disease during and after 
chemotherapy of patients with SCC. 
Neural Cell Adhesion Molecule (NCAM) 
Cell surface receptors involved in cellular adhe- 
sion have been identified on several cell types, 
including haematopoietic, muscle and neural tissues 
(73-75). The largest number of antibodies to SCLC 
have been found to react with the cluster-l antigen, 
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a 145KDa molecule later identified as the neural 
cell adhesion molecule (NCAM) (76). Neural cell 
adhesion molecule functions as a homophilic adhe- 
sion molecule. Recently NCAM expression in lung 
tumour cell lines have been proved to be associated 
with the expression of neuroendocrine markers of 
differentiation, regardless of the histological type of 
lung cancer (77). The expression of NCAM was 
found to be bown-regulated in the rare small cell 
lung cancer cell lines growing attached to substrate 
(78). Recently, Komminoth et al. (79) have immuno- 
histochemically examined the expression of sialylated 
NCAM in a small number of SCLCs and bronchial 
or gastrointestinal carcinoids. There is increasing 
evidence that NCAM not only exists in membrane- 
bound form but is also released from the cell surface 
(80). A soluble form of NCAM has been described in 
conditioned media from neural or muscle cells and in 
different body fluids (81-83). Positivity for NCAM 
has been found in tumours of varying origins such as 
SCLC (84) some NSCLC (SS), neuroblastoma (86) 
nephroblastoma (87) pheocromocitoma (79) and 
pituitary tumours (77). Recently Kibbelar et al. (88) 
demonstrated, using immunohistochemistry methods 
within a group of radically resected NSCLC 
tumours, NCAM-positive patients to have a signifi- 
cantly shortened overall survival and disease-free 
interval in comparison with patients with NCAM- 
negative tumours. Jacques et al. (89) in a study of 221 
patients with SCLC, measured the serum levels of 
NCAM and NSE. They demonstrated that (1) 113 of 
221 (51%) of all patients had NCAM levels higher 
than 20 U ml- ‘, 75 of 221 patients (34%) had NSE 
levels higher than 25 ng ml - i; (2) levels of both 
markers were significantly different in limited and 
extensive disease patients; (3) patients with patho- 
logic NCAM and NSE levels had significantly shorter 
survival times; (4) pre-treatment NSE and NCAM 
levels were positively correlated; and (5) serum 
marker levels were correlated with clinical status 
in the follow-up studies of 19 patients. These data 
are preliminary and have to be validated by larger 
studies. 
Neuron-Specific Enolase (NSE) 
Enolase is a glycolytic enzyme that is widely dis- 
tributed throughout mammalian tissues and is com- 
posed of three distinct subunits: a, j3 and y (90,91). 
Neuron-specific enolase (NSE) was identified as 
isoenzymes y-y (92). Large amounts of NSE have 
been detected in neuroendocrine cells (93) and in 
neurogenic tumours (94-96). Neuron-specific enolase 
has been found to be a useful marker in patients with 
SCLC. An elevated pre-treatment level of serum NSE 
has been reported in 40-70% of patients with local 
disease, and in 83-98% of patients with extensive 
SCLC (97-101). The NSE levels have generally been 
claimed to change along with the course of disease 
(97,100,102,103). Neuron-specific enolase is an intra- 
cellular enzyme involved in energy production, and 
therefore serum NSE may be a reflection of the 
turnover and cell death rate (104). Consecutive daily 
NSE determinations during chemotherapy have 
revealed a transient increase immediately after the 
start of cytotoxic drug administration (tumour lysis 
syndrome), followed by a decrease to the normal 
level in complete or partial responders (lOl-103,105). 
This phenomenon seems to indicate tumour sensitiv- 
ity to chemotherapy (106). Several reports have 
addressed the prognostic capability of NSE. A sig- 
nificant inverse correlation between NSE levels and 
survival has been found in univariate analysis 
(20,107-l 1 l), whereas more equivocal results were 
reported by Jorgensen et al. (110) and Gronowitz 
et al. (20) using multivariate methods. Relatively few 
studies have been devoted to defining the role of 
serum NSE in NSCLC. The percentage of patients 
with elevated NSE levels may be 1141% in NSCLC 
(100,112-l 14) confirming the hypothesis that all 
human lung cancers have a common cellular origin 
and that neuroendocrine differentiation may be 
found in all histologic subtypes of lung cancer (115). 
Preliminary data suggest that NSCLC detected by 
neuroendocrine markers are more sensitive to 
cytotoxic chemotherapy than non-neuroendocrine 
NSCLC (116119), but may have a shortened sur- 
vival (88, 120). In this context it is worthwhile to note 
that NSE is not a specific marker for neuroendocrine 
differentiation, and elevated serum NSE levels cannot 
be taken as conclusive proof of neuroendocrine 
differentiation (121). The value of serum NSE 
assay remains, therefore, limited to patients with 
cytohistologically-proved diagnoses. 
Creatine Phosphokinase-BB (CPK-BB) 
Creatine phosphokinase (CPK) consists of three 
principal cytoplasmic isoenzymes; MM, MB, and BB 
(122). Creating phosphokinase is an enzyme that 
catalyses the transfer of a high energy phosphate 
from creatine phosphate to adenosine diphosphate. 
The skeletal muscle contains relatively large amounts 
of isoenzyme MM (123) the cardiac muscle contains 
significant amounts of MB, and CPK-BB is found 
mainly in brain and smooth muscle (123). Increased 
concentrations of CPK-BB have been reported to 
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occur in the serum of patients with carcinomas of the 
prostate (124), breast (125) and stomach (126). 
Coolen and Pragay (127) in 1979 were the first to 
report elevated levels of CPK-BB isoenzyme in the 
sera of SCLC patients. CPK-BB was found in high 
concentration in SCLC tumour specimens and cell 
lines (128). Other authors examined the correlation 
between the level of this enzyme and the stage of 
disease (128,129). Gazdar et al. (128) found that 
CPK-BB was mainly elevated in advanced stages, 
and depended on tumour size. Similar results were 
reported by Carney et al. (129) who reported an 
increase of CPK-BB in 2% of patients with limited 
disease and in 41% with extensive disease. These 
authors also suggested a correlation between the 
number of metastatic sites and the level of enzyme 
(19% of all patients with single metastases and 100% 
with multiple metastases had elevated values of CPK- 
BB). Jacques et al. (108) found levels of CPK-BB 
above 10 ng ml ~ i in 40 of 129 SCLC patients (32%). 
A subgroup analysis showed that patients with liver 
and brain marrow metastases had an elevation of this 
enzyme. In these patients, the same authors observed 
a correlation between pre-treatment CPK-BB and 
response to therapy. As to prognosis, subjects with 
pathologic levels of the enzyme had shorter survival 
times than patient with normal levels (108). High 
concentration of this isoenzyme in cerebrospinal fluid 
seems to be useful to distinguish between meningeal 
spread and parenchymal cerebral metastases (130). 
Chromogranin A (ChrA) 
Chromogranin A (ChrA) was initially described as 
a protein co-stored and co-released with catechol- 
amines (131,132). It is a 68 000 dalton acidic protein 
that has been found in the neurosecretory granules of 
normal endocrine tissues and malignant APUD cells 
(133-l 37). O’Connor and Deftos (138) observed that 
measurements of plasma chromogranin A were use- 
ful in the evaluation endocrine nature of a neoplasm 
or in the recognition of the neoplastic nature of 
endocrine tissues that do not produce any other 
peptide hormones. Immunohistochemical techniques 
in SCLC have produced contrasting reports: 
Nakajama et al. (139) found a positive reaction to 
chromogranin A in five out of 29 biopsy specimens of 
SCLC, whilst Said et al. (140) failed to demonstrate 
any positive histochemical reaction in 12 SCLC cases. 
Another study (141) postulated the potential value of 
this marker for the subset of SCLC cell lines: the 
authors found significant chromogranin A released 
into the culture medium in three out of five SCLC 
and in only one out of five NSCLC cell lines. Sobol 
et al. (142) assayed the sera of 46 SCLC patients: 52% 
of patients with limited disease (LD) and 72% with 
extensive disease (ED) had elevated levels of 
chromogranin A. In the same study, four patients 
with elevated levels of this substance, originally clas- 
sified as NSCLC, were eventually found to have a 
mixed SCLC-NSCLC histology (142). Recent work 
by Johnson et al. (143) measured serum levels of 
chromogranin A, NSE, LDH and CEA at presenta- 
tion and during treatment, remission and relapse of 
154 SCLC patients. Like NSE and LDH, 
chromogranin A was correlated with the stage of 
disease. The response to therapy was best correlated 
with the presentation levels of ChrA. The prediction 
of relapse was mostly reliable with ChrA, since 52% 
of progressed patients recorded rising levels of this 
marker before any clinical sign. 
Soluble Interleukin-2 Receptor (sIL-2R) 
Activation of T lymphocytes leads to the expres- 
sion of interleukin-2 receptors (IL-2R) on the cell 
surface (144) as well as to the release of soluble IL-2R 
(sIL-2R) molecules into the circulation (145). T lym- 
phocytes are the predominant IL-2R bearing cells 
(146) and hence the serum sIL-2R level provides a 
satisfactory indication of T-cell activation in vivo. 
Increased sIL-2R levels have been found to be 
associated with lymphoid cell activation (147-150) 
lymphoproliferative disorders (15 l), and solid 
tumours (152). Also in the serum of patients with 
SCLC and NSCLC, sIL-2R levels have been reported 
to be elevated (151,153-155). Buccheri et al. found 
increased concentrations of sIL-2R in 126 lung can- 
cer patients, in comparison with healthy volunteers 
and patients with pulmonary benign diseases (155). 
Pre-treatment sIL-2R correlated with neither the 
extent of disease nor with the histotype. On the 
contrary, post-treatment levels of the receptor corre- 
lated significantly with the status of disease, particu- 
larly in non-surgical patients. Also, patients with 
abnormal levels of sIL-2R were found to have a 
worse prognosis (155). In patients with adenocarci- 
noma of the lung, Ginns et al. (153) found that the 
serum concentration of sIL-2R did not correlate with 
the extent of the disease, degree of differentiation, or 
presence of symptoms. Conversely, in SCC patients, 
the peripheral blood concentration of the soluble 
receptor appeared to relate inversely to the severity of 
illness, since the highest levels were found in patients 
who were asymptomatic for a stage I disease. 
Recently, Chan et al. (156) confirmed that serum 
sIL-2R is significantly higher in patients with 
NSCLC if compared with control subjects. The 
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serum levels of sIL-2R were higher in patients with 
extensive intrathoracic disease detected at operation 
but without distant metastasis, than in patients with 
localized resectable tumour. However, there was no 
difference in patients with metastatic disease com- 
pared to those with non-metastatic tumours. Tisi 
et al. (157) evaluated the influence of changes in 
sIL-2R serum levels during the peri-operative period 
on early relapse rate of 60 patients with operable 
NSCLC. Serum levels were measured before surgery 
and 7 and 30 days after surgery. The study suggests 
that the persistence of increased sIL-2R levels in the 
post-operative period might be associated with a 
higher early relapse rate. Conflicting reports on 
sIL-2R implies that there are probably multiple 
factors influencing the degree of T lymphocyte acti- 
vations in addition to tumour load, and that further 
studies will be necessary for better defining the role of 
this marker. 
Conclusion 
The WHO pathologic description of malignant 
tumours classified lung cancers in SCLC and NSCLC 
(158). Recently, however, data from TM studies have 
indicated that overlaps exist between SCLC and 
NSCLC, supporting the concept that all human lung 
tumours have a common cellular origin and that 
neuroendocrine (NE) differentiation may be found 
in all histologic types of lung cancers (112,113,115). 
NE differentiation may be an important prognostic 
feature of NSCLC, with increased response to 
chemotherapy and improved survival (114). Several 
TMs associated with lung cancer have been investi- 
gated in recent years, yet the issue concerning their 
clinical role remains partly unanswered. To date, no 
single marker for the screening of asymptomatic 
patients has been found. The sensitivity increases 
using multiple marker analysis but there is a consist- 
ent loss in specificity. Therefore it remains very 
difficult to detect a lung tumour at an early clinical 
stage with serum marker measurements. On the con- 
trary, TMs may predict the behaviour and prognosis 
of lung cancer and may be useful to monitor the 
post-operative course of disease. The determination 
of TMs will eventually lead to a better understanding 
of the biological properties of bronchogenic carci- 
noma. Biological studies on TMs may represent a 
promising avenue towards new treatment strategies, 
as well as a promising attempt towards secondary 
prevention. 
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